Immune checkpoints are regulatory pathways in the immune system that modulate immune responses and maintain self-tolerance. They are crucial for preventing autoimmune reactions but can be exploited by tumors to avoid immune destruction. These checkpoints act as "brakes" on the immune system, limiting the intensity and duration of immune responses to minimize damage to normal tissues.

Antibody-drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs) represent two major advances in the field of cancer immunotherapy. While both approaches have achieved notable successes, especially in targeting specific cancers, their individual limitations, such as restricted efficacy in certain tumor types and adverse side effects, present challenges. Combining these two therapies has emerged as a promising strategy to address these shortcomings.

Discover Biointron's anti-mouse antibodies for studying immune pathways in murine models. Explore PD-1, PD-L1, & CTLA-4 antibodies for cancer, immunology, & autoimmune research.

Discover how immune checkpoint inhibitors like PD-1 & CTLA-4 blockers are transforming cancer treatment. Learn about synergies with antibody therapeutics.

Immune checkpoint blockade antibody therapy is an approach in cancer treatment that uses the body's immune system to target and destroy cancer cells. Immune checkpoints are regulatory pathways in immune cells that cancer cells exploit to evade detection. Key immune checkpoints include PD-1, PD-L1, and CTLA-4. By blocking these pathways, antibodies like pembrolizumab, nivolumab, and ipilimumab allow T-cells to recognize and attack cancer cells more effectively.

The 7th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference 2024 was held in Boston, MA on 20-21 June, 2024. The event brought together academics and scientists from research institutes and biopharmaceutical companies to discuss the latest updates, challenges, and future directions in immuno-oncology research.